Abstract
A hybridoma, F133, that produces macrophage activation factor (MAF) after mitogen stimulation was developed by fusing the AKR-derived BW5147 thymoma with alloantigen-stimulated C3H/HeJ splenocytes. F133 supernatants were shown to contain MAF, migration inhibition factor, and a factor capable of suppressing the plaque-forming response to sheep erythrocytes but not lymphotoxin, interleukin II, or interferon. Both concanavalin A (Con A) and phytohemagglutinin (PHA) induced MAF production by F133. Time course and dose-response experiments showed that maximal concentrations of MAF were present 48 hr after stimulation with either 1.5 μg/ml Con A or 6 μg/ml PHA. F133 and normal splenocyte MAF preparations shared physicochemical properties in that heating at 100 °C for 30 min abolished MAF activity while 56 °C for 30 min or 100 °C for 2 min had little effect. In addition, both MAF preparations were dependent on the presence of lipopolysaccharide for macrophage activation and each was inactivated by pH 4.0 or pH 10 treatment while pH 6.0 and pH 8.0 had little effect. Also, pretreatment of both MAF preparations with either trypsin or chymotrypsin inactivated MAF activity.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 311-321 |
| Number of pages | 11 |
| Journal | Cellular Immunology |
| Volume | 68 |
| Issue number | 2 |
| DOIs | |
| State | Published - Apr 1982 |
Funding
I This work was supported by a Biomedical Research Support Grant 88593 from The Jewish Hospital of St. Louis and Public Health Service Grant 1 R26 CA 28860 from the National Cancer Institute through the National Bladder Cancer Project. ’ Author to whom reprint requests should be addressed. ’ Abbreviations used: MAF, macrophage activation factor; LPS, lipopolysaccharide; MIF, migration inhibition factor; IL-2, interleukin II; MEM, minimal essential medium; DME, Dulbecco’s modified essential medium; PEG, polyethylene glycol; IFN, interferon; IFN,, gamma (immune) interferon.
ASJC Scopus subject areas
- Immunology